(June 16, 2020, 10:55 AM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on June 8 denied review of two Ninth Circuit U.S. Court of Appeals rulings affirming certification of a national refund class of diabetics who purchased the drug Actos but who allegedly weren’t warned that the drug could cause bladder cancer in certain patients (Takeda Pharmaceutical Company Limited, et. al. v. Painters and Allied Trades District Council 82 Health Care Fund, et al., No. 19-1069, U.S. Sup.)....